Molecular mechanisms of liver cancer metastasis

Molecular Aspects of Hepatocellular Carcinoma

Volumn , Issue , 2012, Pages 86-105

  Balmer, Maria L ^a,b   Dufour, Jean F ^a,b  

^a Hepatology   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiogenesis; Apoptosis; Cadherins; Cancer; Growth factors; Hypoxia; Immunity; Metastasis; Migration

Indexed keywords

EID: 84882567232     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805072711201010086     Document Type: Chapter

References (112)

1. Tischoff, I., Tannapfel, A. Hepatocellular carcinoma and cholangiocarcinoma different prognosis, pathogenesis and therapy. Zentralbl Chir., 2007, 132(4): 300-305.
2. Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell., 2000, 100(1): 57-70.
3. Plopper, H.S.F. Primary Hepatic Carcinomas. New York, McGraw-Hill, 1957.
4. Giannelli, G., Pierri, F., Trerotoli, P., et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol. Res., 2002, 24(1), 50.
5. Shimada, K., Sano, T., Sakamoto, Y., Kosuge, T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer., 2005, 104(9): 1939-1947.
6. Nakano, S., Haratake, J., Okamoto, K., Takeda, S. Investigation of resected multinodular hepatocellular carcinoma: assessment of unicentric or multicentric genesis from histological and prognostic viewpoint. Am. J. Gastroenterol., 1994, 89(2): 189-193.
7. Yasui,M., Harada,A., Nonami,T., et al. Potentially multicentric hepatocellular carcinoma: clinicopathologic characteristics and postoperative prognosis. World J Surg., 1997, 21(8): 860-864, discussion 864-865.
8. Ng, I.O., Guan, X.Y., Poon, R.T., Fan, S.T., Lee, J.M. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J. Pathol., 2003, 199(3): 345-353.
9. Katyal, S., Oliver, J.H., Peterson, M.S., Ferris, J.V., Carr, B.S., Baron, R.L. Extrahepatic metastases of hepatocellular carcinoma. Radiology., 2000, 216(3): 698-703.
10. Shimada, M., Yamashita, Y., Aishima, S., Shirabe, K., Takenaka, K., Sugimachi, K. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br. J. Surg., 2001, 88(11): 1463-1466.
11. Chou, F.F., Sheen-Chen, S.M., Chen, C.L., Chen, Y.S., Chen, M.C. Prognostic factors of resectable intrahepatic cholangiocarcinoma. J. Surg Oncol., 1995, 59(1): 40-44.
12. Yang, J., Yan, L.N. Current status of intrahepatic cholangiocarcinoma. World J. Gastroenterol., 2008, 14(41): 6289-6297.
13. Tannapfel, A., Engeland, K., Weinans, L., et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br. J. Cancer., 1999, 80(7): 1069-1074.
14. Davis, S.D. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology., 1991, 180(1): 1-12.
15. Kim, Y.J., Yun, M., Lee, W.J., Kim, K.S., Lee, J.D. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur. J. Nucl. Med. Mol. Imaging., 2003, 30(11): 1467-1472.
16. Marsh, J.W., Dvorchik, I., Subotin, M., et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology., 1997, 26(2): 444-450.
17. Blum, H.E. Hepatocellular carcinoma: therapy and prevention. World J. Gastroenterol., 2005, 11(47): 7391-7400.
18. Yamamoto, M., Takasaki, K., Yoshikawa, T. Lymph node metastasis in intrahepatic cholangiocarcinoma. Jpn. J. Clin. Oncol., 1999, 29(3),147-150.
19. Bogenrieder, T., Herlyn, M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene., 2003, 22(42): 6524-6536.
20. Dvorak, H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 1986, 315(26): 1650-1659.
21. Hsu, M.Y., Meier, F., Herlyn, M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation., 2002, 70(9-10), 522-536.
22. Chambers, A.F., Wilson, S.M., Kerkvliet, N., O'Malley, F.P., Harris, J.F., Casson, A.G. Osteopontin expression in lung cancer. Lung Cancer., 1996, 15(3): 311-323.
23. Al-Mehdi, A.B., Tozawa, K., Fisher, A.B., Shientag, L., Lee, A., Muschel, R.J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med., 2000, 6(1): 100-102.
24. Maniotis, A.J., Folberg, R., Hess, A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol., 1999, 155(3): 739-752.
25. Sugino, T., Yamaguchi, T., Hoshi, N., et al. Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin. Exp. Metastasis., 2008, 25(7): 835-841.
26. Cavallaro, U., Christofori, G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim. Biophys. Acta., 2001, 1552(1): 39-45.
27. Johnson, J.P. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev., 1999, 18(3): 345-357.
28. Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell., 2002, 110(6): 673-687.
29. Hehlgans, S., Haase, M., Cordes, N. Signaling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta., 2007, 1775(1): 163-180.
30. Brooks, P.C., Clark, R.A., Cheresh, D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science., 1994, 264(5158): 569-571.
31. Goodwin, M., Yap, A.S. Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol., 2004, 35(8-9), 839-844.
32. Leckband, D., Prakasam, A. Mechanism and dynamics of cadherin adhesion. Annu. Rev. Biomed. Eng., 2006, 8, 259-287.
33. Mege, R.M., Gavard, J., Lambert, M. Regulation of cell-cell junctions by the cytoskeleton. Curr. Opin. Cell Biol., 2006, 18(5): 541-548.
34. Jeanes, A., Gottardi, C.J., Yap, A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene., 2008, 27(55): 6920-6929.
35. Li, G., Herlyn, M. Dynamics of intercellular communication during melanoma development. Mol. Med. Today., 2000, 6(4): 163-169.
36. Friedl, P., Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer., 2003, 3(5): 362-374.
37. Larue, L., Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene., 2005, 24(50): 7443-7454.
38. Nobes, C.D., Hall, A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell., 1995, 81(1): 53-62.
39. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell., 2004, 117(7): 927-939.
40. Alexandrova, A.Y. Evolution of cell interactions with extracellular matrix during carcinogenesis. Biochemistry (Mosc)., 2008, 73(7): 733-741.
41. Kim, R., Emi, M., Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology., 2007, 121(1): 1-14.
42. Nagao, M., Nakajima, Y., Hisanaga, M., et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology., 1999, 30(2): 413-421.
43. Nagao, M., Nakajima, Y., Kanehiro, H., et al. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology, 2000, 32(3): 491-500.
44. Wu, X.Z., Xie, G.R., Chen, D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2007, 22(8): 1178-1182.
45. Aravalli, R.N., Steer, C.J., Cressman, E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48(6): 2047-2063.
46. Giles, R.H., van Es, J.H., Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta., 2003, 1653(1): 1-24.
47. Polakis, P. Wnt signaling and cancer. Genes Dev., 2000, 14(15): 1837-1851.
48. Bafico, A., Liu, G., Yaniv, A., Gazit, A., Aaronson, S.A. Novel mechanism of Wnt signaling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol., 2001, 3(7): 683-686.
49. Qin, X., Zhang, H., Zhou, X., et al. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res., 2007, 150(5): 281-294.
50. Zhu, H., Chen, X.P., Zhang, W.G., Luo, S.F., Zhang, B.X. Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J. Gastroenterol., 2005, 11(25): 3855-3859.
51. Suzuki, T., Yano, H., Nakashima, Y., Nakashima, O., Kojiro, M. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J. Gastroenterol. Hepatol., 2002, 17(9): 994-1000.
52. Itoh, T., Shiro, T., Seki, T., et al. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int. J. Mol. Med., 2000, 6(2): 137-142.
53. Jeng, K.S., Sheen, I.S., Chen, B.F., Wu, J.Y. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg., 2000, 135(11): 1329-1333.
54. Yoon, S., Seger, R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors., 2006, 24(1): 21-44.
55. Chang, F., Steelman, L.S., Lee, J.T., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia., 2003, 17(7): 1263-1293.
56. Kauffman, E.C., Robinson, V.L., Stadler, W.M., Sokoloff, M.H., Rinker-Schaeffer, C.W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol., 2003, 169(3): 1122-1133.
57. Lee, H.C., Tian, B., Sedivy, J.M., Wands, J.R., Kim, M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology., 2006, 131(4): 1208-1217.
58. Guo, K., Liu, Y., Zhou, H., et al. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci., 2008, 99(3): 486-496.
59. El-Assal, O.N., Yamanoi, A., Soda, Y., et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology., 1998, 27(6): 1554-1562.
60. Sugimachi, K., Tanaka, S., Taguchi, K., Aishima, S., Shimada, M., Tsuneyoshi, M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J. Clin. Pathol., 2003, 56(11): 854-860.
61. Yasuda, S., Arii, S., Mori, A., et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J. Hepatol., 2004, 40(1): 117-123.
62. von Marschall, Z., Cramer, T., Hocker, M., Finkenzeller, G., Wiedenmann, B., Rosewicz, S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut., 2001, 48(1): 87-96.
63. Lee, S.W., Lee, Y.M., Bae, S.K., Murakami, S., Yun, Y., Kim, K.W. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem. Biophys. Res. Commun., 2000, 268(2): 456-461.
64. Tsukamoto, A., Kaneko, Y., Yoshida, T., Ichinose, M., Kimura, S. Regulation of angiogenesis in human hepatomas: possible involvement of p53-inducible inhibitor of vascular endothelial cell proliferation. Cancer Lett., 1999, 141(1-2), 79-84.
65. Song, P.M., Zhang, Y., He, Y.F., et al. Bioinformatics analysis of metastasis-related proteins in hepatocellular carcinoma. World J. Gastroenterol., 2008, 14(38): 5816-5822.
66. Li, D.Y., Sorensen, L.K., Brooke, B.S., et al. Defective angiogenesis in mice lacking endoglin. Science., 1999, 284(5419): 1534-1537.
67. Yang, L.Y., Lu, W.Q., Huang, G.W., Wang, W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer., 2006, 6, 110.
68. Klosek, S.K., Nakashiro, K., Hara, S., Shintani, S., Hasegawa, H., Hamakawa, H. CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem. Biophys. Res. Commun., 2005, 336(2): 408-416.
69. Ke, A.W., Shi, G.M., Zhou, J., et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology., 2009, 49(2): 491-503.
70. Deveraux, Q.L., Reed, J.C. IAP family proteins-suppressors of apoptosis. Genes Dev., 1999, 13(3): 239-252.
71. Mazzaferro, V., Regalia, E., Doci, R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med., 1996, 334(11): 693-699.
72. Shi, Y.H., Ding, W.X., Zhou, J., et al. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology., 2008, 48(2): 497-507.
73. Li, M., Liu, X., Zhou, S., Li, P., Li, G. Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes. BMC Cancer., 2005, 5, 96.
74. Dudich, E., Semenkova, L., Dudich, I., Denesyuk, A., Tatulov, E., Korpela, T. Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction. FEBS J., 2006, 273(16): 3837-3849.
75. Semenkova, L., Dudich, E., Dudich, I., et al. Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Eur. J. Biochem., 2003, 270(21): 4388-4399.
76. Zhang, Y., Li, Q., Liu, N., et al. Detection of MAGE-1, MAGE-3 and AFP mRNA as multimarker by real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Hepatogastroenterology., 2008, 55(88): 2200-2206.
77. Kumada, T., Nakano, S., Takeda, I., et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J. Hepatol., 1999, 30(1): 125-130.
78. Coppola, D., Szabo, M., Boulware, D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res., 2004, 10(1 Pt 1), 184-190.
79. Oates, A.J., Barraclough, R., Rudland, P.S. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis., 1997, 17(1): 1-15.
80. Thalmann, G.N., Sikes, R.A., Devoll, R.E., et al. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res., 1999, 5(8): 2271-2277.
81. Tuck, A.B., O'Malley, F.P., Singhal, H., et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med., 1997, 121(6): 578-584.
82. Emani, S., Zhang, J., Guo, L., Guo, H., Kuo, P.C. RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer Surgery., 2008, 14 (6), 803-812.
83. Fujii, T., Koshikawa, K., Nomoto, S., et al. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J. Hepatol., 2004, 41(1): 104-111.
84. Sasaki, H., Nagura, K., Ishino, M., Tobioka, H., Kotani, K., Sasaki, T. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J. Biol. Chem., 1995, 270(36): 21206-21219.
85. van Buul, J.D., Anthony, E.C., Fernandez-Borja, M., Burridge, K., Hordijk, P.L. Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation. J. Biol. Chem., 2005, 280(22): 21129-21136.
86. Bouchard, M.J., Wang, L.H., Schneider, R.J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science., 2001, 294(5550): 2376-2378.
87. Sun, C.K., Ng, K.T., Sun, B.S., et al. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br. J. Cancer., 2007, 97(1): 50-57.
88. Goll, D.E., Thompson, V.F., Li,H., Wei, W., Cong, J. The calpain system. Physiol. Rev., 2003, 83(3): 731-801.
89. Arthur, J.S., Greer, P.A., Elce, J.S. Structure of the mouse calpain small subunit gene. Biochim. Biophys. Acta., 1998, 1388(1): 247-252.
90. Tan, Y., Dourdin, N., Wu, C., De Veyra, T., Elce, J.S., Greer, P.A. Conditional disruption of ubiquitous calpains in the mouse. Genesis., 2006, 44(6): 297-303.
91. Bai, D.S., Dai, Z., Zhou, J., et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology., 2009, 49(2): 460-470.
92. Goloudina, A., Yamaguchi, H., Chervyakova, D.B., Appella, E., Fornace, A.J.Jr., Bulavin, D.V. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle., 2003, 2(5): 473-478.
93. Kristjansdottir, K., Rudolph, J. Cdc25 phosphatases and cancer. Chem. Biol., 2004, 11(8): 1043-1051.
94. Wang, X.Q., Zhu, Y.Q., Lui, K.S., Cai, Q., Lu, P., Poon, R.T. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma. Clin. Cancer Res., 2008, 14(21): 6813-6820.
95. Iizuka, N., Oka, M., Yamada-Okabe, H., et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet., 2003, 361(9361): 923-929.
96. Ye, Q.H., Qin, L.X., Forgues, M., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med., 2003, 9(4): 416-423.
97. Budhu, A., Forgues, M., Ye, Q.H., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell., 2006, 10(2): 99-111.
98. Tanaka, S., Arii, S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci., 2009, 100(1): 1-8.
99. Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4): 378-390.
100. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell., 2009, 15(3): 232-239.
101. Paez-Ribes, M., Allen, E., Hudock, J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell., 2009, 15(3): 220-231.
102. Bergers, G., Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer., 2008, 8(8): 592-603.
103. Sun, B., Zhang, S., Zhang, D., et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol. Rep., 2006, 16(4): 693-698.
104. Seftor, E.A., Meltzer, P.S., Kirschmann, D.A., et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis., 2002, 19(3): 233-246.
105. Ciardiello, F., Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 2001, 7(10): 2958-2970.
106. Mendelsohn, J., Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21(14): 2787-2799.
107. Ito, Y., Takeda, T., Sakon, M., et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer., 2001, 84(10): 1377-1383.
108. Philip, P.A., Mahoney, M.R., Allmer, C., et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol., 2005, 23(27): 6657-6663.
109. Thomas, M.B., Chadha, R., Glover, K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer., 2007, 110(5): 1059-1067.
110. Greten, T.F., Korangy, F., Manns, M.P., Malek, N.P. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer., 2009, 100(1): 19-23.
111. Fuchs, B.C., Fujii, T., Dorfman, J.D., et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res., 2008, 68(7): 2391-2399.
112. Bergers, G., Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncology., 2005, 7(4): 452-464.